Ketanserin potentiates the prejunctional inhibitory effect of 5-hydroxytryptamine on rat vas deferens

Moritoki, Hideki; Fukuda, Hiroshi; Kanaya, Jun; Ishida, Yoshiteru

doi:10.1111/j.2042-7158.1986.tb04481.x

Cited by 10 publications

(1 citation statement)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Cyproheptadine also has mild anticholinergic and antiserotonergic properties (possibly through blocking 5-HT 1A and 5-HT 2A receptors) (48). Animal data suggested that cyproheptadine potentiates the prejunctional inhibitory effect of 5-HT and attenuates its stimulatory effect in the rat and guinea-pig vas deferens (49,50) suggesting peripheral effects. Additionally, it facilitates sexual behavior of the male rat possibly through antiserotonergic effects (51).…”

Section: Cyproheptadinementioning

confidence: 99%

The drug treatment of delayed ejaculation

Abdel‐Hamid¹,

Elsaied²,

Mostafa³

2016

Transl. Androl. Urol.

View full text Add to dashboard Cite

Delayed ejaculation (DE) is an uncommon and a challenging disorder to treat. It is often quite concerning to patients and it can affect psychosocial well-being. Here we reviewed how DE is treated pharmacologically .We also highlighted specific settings where drugs could be introduced to medical practice. Electronic databases were searched from 1966 to February 2016, including PubMed MEDLINE, EMBASE, EBCSO Academic Search Complete, Cochrane Systematic Reviews Database, and Google Scholar using key words; delayed ejaculation, retarded ejaculation, inhibited ejaculation, drugs, treatment, or pharmacology. To achieve the maximum sensitivity of the search strategy and to identify all studies, we combined “delayed ejaculation” as Medical Subject Headings (MeSH) terms or keywords with each of “testosterone” or “cabergoline” or “bupropion” or “amantadine” or “cyproheptadine” or “midodrine” or “imipramine” or “ephedrine” or “pseudoephedrine” or “yohimbine” or “buspirone” or “oxytocin” or “bethanechol” as MeSH terms or keywords. There are a number of drugs to treat patients with DE including: testosterone, cabergoline, bupropion, amantadine, cyproheptadine, midodrine, imipramine, ephedrine, pseudoephedrine, yohimbine, buspirone, oxytocin, and bethanechol. Although there are many pharmacological treatment options, the evidence is still limited to small trials, case series or case reports. Review of literature showed that evidence level 1 (Double blind randomized clinical trial) studies were performed with testosterone, oxytocin, buspirone or bethanechol treatment. It is concluded that successful drug treatment of DE is still in its infancy. The clinicians need to be aware of the pathogenesis of DE and the pharmacological basis underlying the use of different drugs to extend better care for these patients. Various drugs are available to address such problem, however their evidence of efficacy is still limited and their choice needs to be individualized to each specific case.

show abstract

Section: Cyproheptadinementioning

confidence: 99%

The drug treatment of delayed ejaculation

Abdel‐Hamid¹,

Elsaied²,

Mostafa³

2016

Transl. Androl. Urol.

View full text Add to dashboard Cite

show abstract

Serotonin and Smooth Muscle

Killam¹,

Cohen²

1994

Handbook of Experimental Pharmacology

View full text Add to dashboard Cite

Regional distribution of dopamine, 5-hydroxytryptamine, and noradrenaline in the rat vas deferens

Celuch

Sloley

1988

Neurochem Res

View full text Add to dashboard Cite

The concentrations of dopamine (DA), 5-hydroxytryptamine (5-HT) and noradrenaline (NA) in the rat vas deferens divided in eight or four sections were determined by high performance liquid chromatography with electrochemical detection. Dopamine and NA had the same regional distribution; their concentrations were maximal near the prostatic end and decreased towards the epididymis. The concentration of 5-HT also decreased from the prostatic to the epididymal end, but 5-HT did not follow the same regional distribution as DA and NA. Reserpine (0.02 or 0.2 mg/kg, i.p., 24 hr) and 6-hydroxydopamine (2 x 80 mg/kg, i.v., 6 days) decreased the contents of DA and NA; the concentrations of both amines were modified to a similar extent. Reserpine also diminished the content of 5-HT. Pargyline (200 mg/kg, i.p., 2 hr) increased the concentration of 5-HT while p-chlorophenylalanine (300 mg/kg, oral, 3 days) decreased the contents of the amine in some sections of the vas deferens. This study suggests that DA and NA co-exist in the same sympathetic neurons. Some of the 5-HT could be stored in mast cells as previously proposed, but the finding that tissue content of 5-HT changes after inhibiting the deamination or synthesis of the amine suggests that other source(s) of 5-HT distinct from mast cells exist in the rat vas deferens.

show abstract

Ketanserin potentiates the prejunctional inhibitory effect of 5-hydroxytryptamine on rat vas deferens

Cited by 10 publications

References 18 publications

The drug treatment of delayed ejaculation

The drug treatment of delayed ejaculation

Serotonin and Smooth Muscle

Regional distribution of dopamine, 5-hydroxytryptamine, and noradrenaline in the rat vas deferens

Contact Info

Product

Resources

About